Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florent Grange

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Archives of Dermatology|March 17, 2010
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in FranceFrédérique Durbec, Fabien Vitry, Florence Granel-Brocard, et al.
Acta Dermato-Venereologica|June 4, 2020
Cutaneous Involvement in Waldenström's MacroglobulinaemiaSarah Stien, Eric Durot, Anne Durlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skinEve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, et al.
JAMA Dermatology|March 21, 2014
Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in FranceFlorent Grange, Pascal Joly, Coralie Barbe, et al.
American Journal of Clinical Pathology|June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a reviewTony Petrella, Martine Bagot, Rein Willemze, et al.
The Journal of Investigative Dermatology|March 30, 2018
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg TypeMarie Beylot-Barry, Diane Mermin, Aline Maillard, et al.
JAMA Dermatology|July 16, 2020
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic MelanomaAngélique Brunot, Jean-Jacques Grob, Geraldine Jeudy, et al.
The Journal of Investigative Dermatology|August 28, 2017
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer NetworkJulie Delyon, Sylvie Chevret, Thomas Jouary, et al.
Journal of the American Academy of Dermatology|July 31, 2012
Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a familyEve Maubec, Valérie Chaudru, Hamida Mohamdi, et al.
Blood|February 5, 2005
WHO-EORTC classification for cutaneous lymphomasRein Willemze, Elaine S Jaffe, Günter Burg, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Archives of Dermatology|March 17, 2010
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in FranceFrédérique Durbec, Fabien Vitry, Florence Granel-Brocard, et al.
Acta Dermato-Venereologica|June 4, 2020
Cutaneous Involvement in Waldenström's MacroglobulinaemiaSarah Stien, Eric Durot, Anne Durlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skinEve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, et al.
JAMA Dermatology|March 21, 2014
Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in FranceFlorent Grange, Pascal Joly, Coralie Barbe, et al.
American Journal of Clinical Pathology|June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a reviewTony Petrella, Martine Bagot, Rein Willemze, et al.
The Journal of Investigative Dermatology|March 30, 2018
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg TypeMarie Beylot-Barry, Diane Mermin, Aline Maillard, et al.
JAMA Dermatology|July 16, 2020
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic MelanomaAngélique Brunot, Jean-Jacques Grob, Geraldine Jeudy, et al.
The Journal of Investigative Dermatology|August 28, 2017
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer NetworkJulie Delyon, Sylvie Chevret, Thomas Jouary, et al.
Journal of the American Academy of Dermatology|July 31, 2012
Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a familyEve Maubec, Valérie Chaudru, Hamida Mohamdi, et al.
Blood|February 5, 2005
WHO-EORTC classification for cutaneous lymphomasRein Willemze, Elaine S Jaffe, Günter Burg, et al.
Pageof 8